Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento’s lead products are multiple late-stage biosimilar and biobetter antibodies as well as clinical CAR-T therapies targeting solid tumors. Sorrento has a portfolio of preclinical immuno-oncology antibody programs and antibody drug conjugates (ADCs). Through our subsidiary TNK Therapeutics, we are developing adoptive immunotherapies utilizing T cell as well as Natural Killer (NK) cell.  Sorrento’s joint venture company LA Cell is developing cell-internalizing mAbs against undruggable intracellular targets.